The Immunobiological Technology Institute (Biomanguinhos) guarantees the brazilian self-sufficiency in essential vaccines to respond to public health demands of the brazilian vaccination schedule of the Ministry of Health.
The institute is basically oriented to produce vaccines to DTP and Hib, yellow fever, haemophilus influenzae type B (Hib), meningitis A and C, poliomyelitis and the measles, mumps, and rubella vaccine (MMR).
The institute produces the combined DTP and Haemophilus influenzae B (Hib) vaccine is also known as tetravalent, since it provides protection against diphtheria, tetanus, whooping cough and severe infections by the Haemophilus influenzae type B.
Biomanguinhos is internationally recognized as a yellow fever vaccine manufacturer. Since 1937, vaccinal preparations are obtained in their laboratories from the attenuated strain 17D of the Yellow Fever virus.
The institute started the supply of the combined Hib vaccine at 1999. This immunizing agent provides protection against severe infections caused by the Haemophilus influenzae type B, as meningitis and pneumonia.
In the 70's, Biomanguinhos signed a technical cooperation agreement with Mèrieux Institute from France and since then is been produced the polysaccharidic vaccine against meningococcus serogroups A and C.
The vaccine used in the country is produced by Biomanguinhos from an imported monovalent viral concentrate (bulk), according to the regulations of the World Health Organization (WHO). Strains of attenuated Sabin virus types I, II and III spread in human diploid cell culture (MRC5) are being used.
In October of 2003, Biomanguinhos and the company GlaxoSmithKline signed a technological transfer agreement of the measles, mumps, and rubella vaccine (MMR), which was the only immunobiologic product included in the basic vaccination schedule and still being imported by the Ministry of Health.